...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!



Awakn Life Sciences to Commence Trading on the NEO Exchange Under the Symbol 'AWKN'

  • Strategic focus on developing and delivering psychedelic medicines to treat Addiction.
  • Strong psychedelic drug development pipeline targeting Addiction.
  • First mover advantage for clinics in the UK and the EU with 400m people and CAD$25TR GDP.
  • The leading research and clinical team in the industry focused on using psychedelics to treat Addiction.
  • Multiple scalable revenue streams across drug development and clinical delivery.

Awakn logoset 300x100

Hub On AGORACOM / Corporate Profile / Recent Interview



Message: US to shell out $1.2B for sup­plies of Mer­ck­'s po­ten­tial Covid-19 an­tivi­ral.

Hey, you're right Tada on that $705 per course! That's why it's important to keep an eye out for the competition here! We blow them out of the water re pricing, now we just need to see how we do in human trials!

They've got Merck though, and...here we go again on the FDA/BP political angle.

New Message
Please login to post a reply